or Try an Advanced Search...

    Technical Analysis for GERN - Geron Corporation

    Grade Last Price % Change Price Change
    C 3.90 0.00% 0.00
    GERN closed unchanged on Thursday, May 16, 2024, on 39 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical GERN trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Crossed Above 20 DMA Bullish 0.00%
    180 Bullish Setup Bullish Swing Setup 0.00%
    Gapped Up Strength 0.00%
    20 DMA Resistance Bearish 5.98%
    Down 3 Days in a Row Weakness 5.98%
    Fell Below 20 DMA Bearish 4.28%
    20 DMA Support Bullish 2.63%
    Outside Day Range Expansion 2.63%
    Older End-of-Day Signals for GERN ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 2 hours ago
    Possible NR7 about 4 hours ago
    Possible Inside Day about 4 hours ago
    10 DMA Support about 5 hours ago
    60 Minute Opening Range Breakdown about 6 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    GERN Chart by TradingView
    Basic chart:

    Profile

    Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Biology Stem Cell Senescence Geron Corporation Haematopoiesis

    Is GERN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 3 Geron Corporation (NASDAQ:GERN) Q1 2024 Earnings Call Transcript
    May 3 This Is Why Geron Corporation's (NASDAQ:GERN) CEO Compensation Looks Appropriate
    May 3 Geron Corp (GERN) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves and Financial Health
    May 3 Geron (GERN) Q1 2024 Earnings Call Transcript
    May 3 Q1 2024 Geron Corp Earnings Call
    May 2 Geron Corporation (GERN) Q1 2024 Earnings Call Transcript
    May 2 Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
    May 2 Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
    May 2 The Top 3 Penny Stocks to Buy in April 2024
    May 1 Geron: FDA PDUFA Review With Continued Imetelstat Advancement
    See more GERN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.3
    52 Week Low 1.64
    Average Volume 13,794,374
    200-Day Moving Average 2.44
    50-Day Moving Average 3.38
    20-Day Moving Average 3.81
    10-Day Moving Average 3.82
    Average True Range 0.23
    RSI (14) 57.45
    ADX 38.39
    +DI 22.02
    -DI 12.37
    Chandelier Exit (Long, 3 ATRs) 3.62
    Chandelier Exit (Short, 3 ATRs) 4.04
    Upper Bollinger Bands 4.13
    Lower Bollinger Band 3.49
    Percent B (%b) 0.64
    BandWidth 16.86
    MACD Line 0.12
    MACD Signal Line 0.16
    MACD Histogram -0.0366
    Fundamentals Value
    Market Cap 2.12 Billion
    Num Shares 543 Million
    EPS -0.34
    Price-to-Earnings (P/E) Ratio -11.47
    Price-to-Sales 3614.72
    Price-to-Book 3.94
    PEG Ratio -2.38
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.07
    Resistance 3 (R3) 4.06 3.99 4.04
    Resistance 2 (R2) 3.99 3.95 4.00 4.03
    Resistance 1 (R1) 3.95 3.93 3.97 3.96 4.02
    Pivot Point 3.88 3.88 3.90 3.89 3.88
    Support 1 (S1) 3.84 3.84 3.86 3.85 3.78
    Support 2 (S2) 3.77 3.82 3.78 3.77
    Support 3 (S3) 3.73 3.77 3.76
    Support 4 (S4) 3.74